| Literature DB >> 29610197 |
Fabio Gsaller1,2, Takanori Furukawa1, Paul D Carr1, Bharat Rash1, Christoph Jöchl2, Margherita Bertuzzi1, Elaine M Bignell1, Michael J Bromley3.
Abstract
The antifungal drug 5-flucytosine (5FC), a derivative of the nucleobase cytosine, is licensed for the treatment of fungal diseases; however, it is rarely used as a monotherapeutic to treat Aspergillus infection. Despite being potent against other fungal pathogens, 5FC has limited activity against Aspergillus fumigatus when standard in vitro assays are used to determine susceptibility. However, in modified in vitro assays where the pH is set to pH 5, the activity of 5FC increases significantly. Here we provide evidence that fcyB, a gene that encodes a purine-cytosine permease orthologous to known 5FC importers, is downregulated at pH 7 and is the primary factor responsible for the low efficacy of 5FC at pH 7. We also uncover two transcriptional regulators that are responsible for the repression of fcyB and, consequently, mediators of 5FC resistance, the CCAAT binding complex (CBC) and the pH regulatory protein PacC. We propose that the activity of 5FC might be enhanced by the perturbation of factors that repress fcyB expression, such as PacC or other components of the pH-sensing machinery.Entities:
Keywords: 5-flucytosine; Aspergillus fumigatus; CBC; antifungal agents; antifungal drug resistance; pH regulation; pacC; transcription factors
Mesh:
Substances:
Year: 2018 PMID: 29610197 PMCID: PMC5971587 DOI: 10.1128/AAC.02593-17
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191